Please assess the completion status of the following clinical trial:

Trial Title: Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic ischemic heart failure caused by a heart attack~* Scheduled to undergo cardiac surgery for CABG~* Ejection fraction between 15% and 50%~* Presence of an akinetic or dyskinetic region by standard imaging~Exclusion Criteria:~* Glomerular filtration rate of less than 50 mL/min/1.73m2 at study entry~* Contraindication to performance of an MRI scan~* Bone marrow dysfunction, as evidenced by a 20% or more deviation from normal hematocrit, white blood cell count, or platelet values without another explanation~* A coagulopathy condition not due to a reversible cause (i.e., Coumadin)~* Known, serious radiographic contrast allergy~* Known allergies to penicillin or streptomycin~* Organ transplant recipient~* Clinical history of malignancy within 5 years of study entry (e.g., patients with prior malignancy must be disease free for 5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma~* Non-cardiac condition that limits lifespan to less than 1 year~* On chronic therapy with immunosuppressant medication~* Serum positive for HIV, hepatitis B, or hepatitis C~* Female who is pregnant, nursing, or of child-bearing potential and not practicing effective birth control methods

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lower dose mesenchymal stem cell (MSC) injection (Type: EXPERIMENTAL): Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10\^7 cells
- Higher dose MSC injection (Type: EXPERIMENTAL): Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10\^8 cells
- (3) Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo injections

Based on this trial design, predict the completion outcome and termination type (if applicable).